CTLA4 and rheumatoid arthritis: We also examined the clinical efficacy of CTLA4-Ig in RA patients, and found that it partially reverses immunological abnormalities in RA, specifically that CTLA4-Ig decreased the ratio of inflammatory CD14brightCD16+ monocytes and increased the ratio of mDCs (Figures S2 and S11)33, 34, 35.